News

• Regeneron gets $450M for vaccine advancement
  07/07/2020 / 14:40 - TeleTrader
•  
• Regeneron to start Phase 3 virus treatment trials
  07/06/2020 / 13:35 - TeleTrader
•  
• Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
  07/02/2020 / 22:30 - GlobeNewswire
•  
• Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
  07/01/2020 / 17:28 - GlobeNewswire
•  
• Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
  06/29/2020 / 13:15 - GlobeNewswire
•  
• KYMAB WINS SUPREME COURT CASE AGAINST REGENERON
  06/24/2020 / 11:29 - GlobeNewswire
•  
• Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
  06/19/2020 / 13:30 - GlobeNewswire
•  
• Royalty Pharma Appoints Bonnie Bassler, PhD to the Company’s Board of Directors
  06/16/2020 / 14:00 - GlobeNewswire
•  
• Regeneron starts clinical trial of COVID-19 treatment
  06/11/2020 / 13:33 - TeleTrader
•  
• Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
  06/10/2020 / 14:00 - GlobeNewswire
•  
• Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents
  06/03/2020 / 13:00 - GlobeNewswire
•  
• Sanofi completes sale of equity stake in Regeneron
  05/29/2020 / 22:27 - TeleTrader
•  
• Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
  05/29/2020 / 14:00 - GlobeNewswire
•  
• Nasdaq jumps after lower open
  05/28/2020 / 19:58 - TeleTrader
•  
• Nasdaq drops over 1% as pharma stocks fall
  05/27/2020 / 16:09 - TeleTrader